Stribild

Stribild is an antiretroviral remedy. It used to treat HIV-1 infection in adults who have not received antiretroviral therapy before, as well as in HIV-infected patients without any mutations associated with resistance to one of the antiviral components of the remedy.

Active substance.

Elvitegravir 150 mg, tenofovir dizoproxil at a dose of 245 mg, emtricitabine at a dose of 200 mg and a Cobicistat at a dose of 150 mg.

Mechanism of action.

Stribild contains two previously approved remedies against HIV (emtricitabine and tenofovir dizoproxil fumarate), as well as two new ones – elvitegravir and Cobicistat. Elvitegravir is an inhibitor of HIV integrase; Cobicistat is a pharmacokinetic enhancer, inhibits an enzyme that metabolizes certain remedies for HIV treatment, and is used to prolong the effect of elvitegravir. The combination of these remedies provides a complete scheme for the treatment of HIV infection.

The protocol of taking of Stribild.

Stribild should be taken one tablet one time a day before meals.

Efficiency of taking.

Efficiency and good tolerability of Stribild has been confirmed by the positive results of two major studies of Phase III of the remedy. During the first test, Stribild demonstrated efficiency similar to that of Atripla. In the second study, it was no less effective than the direct-acting antiviral remedy – atazanavir in combination with Truvada.

Contraindications of Stribild

Hypersensitivity to one of the components of the remedy, kidney disease.

Side effects of the remedy

Side effects due to Stribild include nausea, vomiting, diarrhea, rapid breathing, drowsiness, weakness, rash, headache, dizziness and muscle pain. Also, when taking Stribild, you can feel a decrease in appetite, insomnia, abdominal pain, digestive problems, flatulence and constipation.
Stribild is suitable for HIV-infected patients who have already taken other drugs during treatment, the drug can be used for both monotherapy and in combination with other drugs. Stribild binds the virus, not allowing replication and propagation, and that leads to an increase in the number of healthy CD4 cells of the patient.
More than half of those who took Stribild for 28 days, reported at least one side effect. Most often, participants complained of fatigue and problems with the gastrointestinal tract. Most side effects were of mild or moderate severity, but three participants were forced to change treatment due to severe diarrhea, abdominal pain, or repeated vomiting.